Business Context and Reporting Period
Company: ImmuCell Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2002
Business Overview: ImmuCell develops, acquires, manufactures, and markets products to improve the health and productivity of cows for the dairy and beef industry. Primary products include FIRST DEFENSE and WIPE OUT DAIRY WIPES. The company is also developing MAST OUT, a non-antibiotic treatment for mastitis.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2002 | Nine Months Ended Sep 30, 2002 |
|---|---|---|
| Total Revenues | $1,385,595 | $4,839,410 |
| Product Sales | $1,307,055 | $4,487,573 |
| Net Income | $30,479 | $176,911 |
| Net Income Per Share (Diluted) | $0.01 | $0.06 |
| Gross Margin (Product Sales) | 48% | 47% |
| Cash and Cash Equivalents | $1,323,336 | $1,323,336 (Ending Balance) |
| Short-term Investments | $295,260 | $295,260 (Ending Balance) |
| Long-term Debt | $0 | $0 |
| Net Cash Provided by Operating Activities | N/A | $331,689 |
Material Changes vs. Prior Period
- Revenue: Total revenues increased 3% ($126,000) for the nine months ended September 30, 2002, compared to the prior year. Product sales decreased slightly (less than 1%) for the nine-month period but increased 3% for the three-month period.
- Profitability: The company reported a net income of $30,479 for the quarter, a turnaround from a net loss of $56,543 in the same quarter of 2001. Nine-month net income increased 7% to $176,911.
- Debt Reduction: In May 2002, the company utilized approximately $405,000 in cash to fully repay its outstanding bank mortgage. As of September 30, 2002, the company has no outstanding bank debt.
- Inventory: Inventories increased significantly from $533,864 at year-end 2001 to $948,953 at September 30, 2002, driven largely by an increase in work-in-process.
- Grant Income: Grant income increased 123% ($126,000) for the nine-month period, largely due to funding for the MAST OUT product development.
Guidance, Outlook, and Risks
- Subsequent Event (License Termination): On October 1, 2002, the company terminated a product license with Kamar, Inc., receiving $930,000. This represents a pre-tax gain of $930,000. Pro forma adjustments indicate this transaction would have reduced nine-month 2002 net income to $5,866 if recognized at the beginning of the period, as it eliminates future sales and costs associated with the product.
- R&D Outlook: Management anticipates an increase in research and development expenses in Q4 2002 and the first three quarters of 2003 as the MAST OUT product advances to clinical trials. The company targets investing 10% to 13% of product sales in R&D, net of grants.
- Liquidity: Management believes capital resources are sufficient to meet working capital requirements for the next twelve months. The company expects to collect approximately $261,000 in accounts receivable related to the terminated license and anticipates receiving an additional $150,000 in grant funding between October 2002 and June 2003.
- Risks: Key risks include regulatory approval for the FIRST DEFENSE product (USDA), potential delays in MAST OUT development, and the need for additional clinical studies if the Reference Standard for FIRST DEFENSE is not requalified.
Investor Verification Checklist
- License Termination Impact: Verify the accounting treatment and cash receipt status of the $930,000 gain from the Kamar license termination and its effect on future revenue streams.
- Inventory Build-up: Investigate the 78% increase in inventory levels, specifically the rise in work-in-process, to ensure it aligns with production schedules and demand.
- MAST OUT Development: Monitor the timeline and cost escalation associated with the clinical trial phase of the MAST OUT product, which may impact short-term profitability.
- Grant Contingencies: Review the terms of the State of Maine grant ($250,000 received) regarding the contingent payback obligation upon commercialization.
- Debt-Free Status: Confirm the company maintains its debt-free status and assess the sustainability of operations without access to traditional bank credit lines.